Cardiology News / Literature Review / 2018-2019 by Chalapas MD, PhD, FESC, Antonios
CARDIOLOGY CORNER
HOSPITAL CHRONICLES 2019, 14(3): 101–111
Cardiology News / Literature Review / 2018-2019
Antonios Ηalapas MD, PhD, FESC
Interventional Cardiologist, As. Director THV Program, Hygeia Hospital, Athens, Greece
1. COMPLETE study: PCI of non-culprit lesions  
in patients with STEMI
Approximately 50% of patients with ST-elevation myo-
cardial infarction (STEMI) have multivessel disease (MVD) 
with significant non-culprit lesions identified at the time of 
primary percutaneous coronary intervention (pPCI) of the 
culprit lesion. PCI of the culprit lesion reduces the risk of 
cardiovascular death or myocardial infarction. Whether PCI 
of non-culprit lesions further reduces the risk of such events 
is unclear. The COMPLETE was a multinational, randomized 
trial that evaluated a strategy of Complete Vs. Culprit-Only 
Revascularization Strategies to Treat MVD after Early PCI for 
STEMI. At a median follow-up of 3 years, the first coprimary 
outcome had occurred in 158 of the 2016 patients (7.8%) in 
the complete-revascularization group as compared with 213 
of the 2025 patients (10.5%) in the culprit-lesion-only PCI 
group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 
to 0.91; P=0.004). The second coprimary outcome had oc-
curred in 179 patients (8.9%) in the complete-revascularization 
group as compared with 339 patients (16.7%) in the culprit-
lesion-only PCI group (hazard ratio, 0.51; 95% CI, 0.43 to 
0.61; P<0.001). For both coprimary outcomes, the benefit of 
complete revascularization was consistently observed regard-
less of the intended timing of non-culprit-lesion PCI (P=0.62 
and P=0.27 for interaction for the first and second coprimary 
outcomes, respectively). Mehta SR, et al. Am Heart J. 2019 
Sep;215:157-166. doi: 10.1016/j.ahj.2019.06.006. 
2. PCI vs. CABG in 3VD or UPLMD: The 10-year 
results of SYNTAX trial
The Synergy between PCI with Taxus and Cardiac Surgery 
(SYNTAX) trial was a non-inferiority trial that compared per-
cutaneous coronary intervention (PCI) using first-generation 
paclitaxel-eluting stents with coronary artery bypass grafting 
(CABG) in patients with de-novo three-vessel and left main 
coronary artery disease, and reported results up to 5 years. 
We now report 10-year all-cause death results. The SYNTAX 
Extended Survival (SYNTAXES) study is an investigator-
driven extension of follow-up of a multicenter, randomized 
controlled trial done in 85 hospitals across 18 North American 
and European countries. Patients with de-novo three-vessel 
and left main coronary artery disease were randomly assigned 
(1:1) to the PCI group or CABG group. Patients with a history 
of PCI or CABG, acute myocardial infarction, or an indication 
for concomitant cardiac surgery were excluded. The primary 
endpoint of the SYNTAXES study was 10-year all-cause 
death, which was assessed according to the intention-to-treat 
principle. Pre-specified subgroup analyses were performed 
according to the presence or absence of left main coronary 
artery disease and diabetes, and according to coronary com-
plexity defined by core laboratory SYNTAX score tertiles. 
From March 2005, to April 2007, 1800 patients were randomly 
assigned to the PCI (n=903) or CABG (n=897) group. At 10 
years, 248 (28%) patients had died after PCI and 212 (24%) 
after CABG (hazard ratio 1·19 [95% CI 0·99–1·43], p=0·066). 
Among patients with three-vessel disease, 153 (28%) of 546 
had died after PCI versus 114 (21%) of 549 after CABG (hazard 
ratio 1·42 [95% CI 1·11–1·81]), and among patients with left 
main coronary artery disease, 95 (27%) of 357 had died after 
PCI versus 98 (28%) of 348 after CABG (0·92 [0·69–1·22], 
pinteraction= 0·023). There was no treatment-by-subgroup 
interaction with diabetes (p interaction= 0·60) and no linear 
trend across SYNTAX score tertiles (p trend=0·20). At 10 
years, no significant difference existed in all-cause death 
between PCI using first-generation paclitaxel-eluting stents 
and CABG. However, CABG provided a significant survival 
benefit in patients with three-vessel disease, but not in pa-
tients with left main coronary artery disease.Thuijs DJFM 
et al. Lancet. 2019 12;394(10206):1325-1334. doi: 10.1016/
S0140-6736(19)31997-X.
3. COLCOT Trial: Colchicine in patients with acute MI
Inflammation plays a central role in the pathophysiology 
of both atherosclerosis and acute coronary artery disease. 
However, previous studies have not demonstrated improved 
cardiovascular outcomes for therapy directly targeted at in-
flammation. Colchicine is an orally administered, potent anti-
inflammatory medication that is indicated for the treatment of 
gout and pericarditis. In the COLCOT trial, over 4700 patients 
with myocardial infarction (MI) were randomly assigned 
to colchicine 0.5mg daily or placebo within 30 days of their 
event (2366 patients were assigned to the colchicine group, 
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and 2379 to the placebo group). At 2 years, the primary end 
point occurred in 5.5% of the patients in the colchicine group, 
as compared with 7.1% of those in the placebo group (hazard 
ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P=0.02). 
The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death 
from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for 
resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for 
myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, 
and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for 
angina leading to coronary revascularization. Diarrhea was 
reported in 9.7% of the patients in the colchicine group and in 
8.9% of those in the placebo group (P=0.35). Pneumonia was 
reported as a serious adverse event in 0.9% of the patients in 
the colchicine group and in 0.4% of those in the placebo group 
(P=0.03). While the results of COLCOT appear promising, 
we do not treat MI patients with colchicine pending additional 
supportive evidence. Jean-Claude Tardif, et al. NEJM, 2019; 
381:2497-2505 DOI: 10.1056/NEJMoa1912388
4. Percutaneous coronary intervention of bifurcation 
stenosis - 3-year results of DKCRUSH-V study.
In 2019, the 3-year follow-up data of the DKCRUSH-V 
study were published; similar to what has been reported at 
1-year follow-up, DK-Crush technique was associated with 
a lower incidence of target lesion revascularization (TLR, 
5.0% vs. 10.3%, P= 0.029) target vessel MI (1.7% vs. 5.8%, 
P= 0.017), and definite or probable stent thrombosis (0.4% vs. 
4.1%, P = 0.006) compared to provisional T stenting. DK-Crush 
technique, however, is a challenging procedure and requires 
skills and expertise; therefore, considering that the findings 
of the DKCRUSH-V study may not be reproduced by centers 
with less experienced operators, the recently published 14th 
consensus document from the European Bifurcation Club 
advocates the use of provisional T-stenting technique for the 
treatment of bifurcations lesions and proposes a two stent 
strategy only in lesions with a complex anatomy, when access 
to the side branch is challenging, or when there is ostial disease 
in the side branches extending >5mm form the carina and/or 
increased calcification.  In the case of a two stent strategy the 
European Bifurcation Club recommends the use of Culotte or 
TAP technique and when the crush technique is considered it 
proposes the use of the DK-crush. Banning AP, et al. Euro-
Intervention 2019;15:90–98 doi: 10.4244/EIJ-D-19-00144.
5. Drug-Eluting Stent Implantation vs. Optimal Medical 
Treatment in Patients With Chronic Total Occlusion 
(DECISION-CTO) trial
In 2019, the Euro-CTO Club published a consensus docu-
ment that summarizes the current evidence discusses the 
indications for chronic total occlusion (CTO) revasculariza-
tion, presents the advances in CTO equipment, and provides 
recommendations about training in CTO PCI. In line with the 
ESC guidelines on myocardial revascularization and taking 
into account the findings of randomized controlled (RCT) 
studies, the EuroCTO Club recommends CTO recanalization 
in the presence of symptoms despite optimal medical therapy; 
in asymptomatic patients, ischemic burden assessment is 
recommended and CTO revascularization is advised if there 
is evidence of increased ischemic burden (>_10% of the left 
ventricular mass). These recommendations are in line with the 
findings of the recently reported Drug-Eluting Stent Implanta-
tion vs. Optimal Medical Treatment in Patients With Chronic 
Total Occlusion (DECISION CTO) trial. This is an open-label, 
multicenter, non-inferiority trial, in which 815 patients with a 
CTO were randomized in 1:1 ratio to complete revasculariza-
tion or to the treatment of the obstructive non-CTO lesions 
whenever these were present. Only one-fourth of the patients 
included in the two groups had a single- vessel disease. At 
4-year follow-up, there was no difference between the two 
groups for the combined endpoint of death, MI, stroke, or 
revascularization (22.4% vs. 22.3%, P = 0.86) or patients’ qual-
ity of life. These findings indicate that in case of multivessel 
disease (MVD) revascularization of the non-CTO lesion and 
re-evaluation of the extent of ischemia and patient symptoms 
should be considered before advocating recanalization of a 
CTO. Limitations of the study included the high crossover 
rate (19.6%) from the non-CTO PCI group to the CTO-PCI 
group within the first days from randomization as well the fact 
that it was underpowered for the primary endpoint as patient 
recruitment was early terminated because of a slow enrolment 
rate. Moreover, the non-inferiority design is not suitable when 
comparing a more costly and potentially risky intervention 
with medical treatment alone. A superiority design and power 
calculation should have been used. In conclusion, both study 
groups (CTO-PCI and no CTO-PCI) were associated with 
substantial quality of life improvements that were sustained 
through 36 months, with no differences between groups in 
the primary quality of life analyses. However, the impact of 
CTO-PCI on clinical outcomes should be tested in large RCT 
that include higher-risk patients with more complex CTOs. 
Lee SW, et al. Circulation 2019;139: 1674–1683, doi: 10.1161/
CIRCULATIONAHA.118.031313.
6. TWILIGHT study: Ticagrelor Monotherapy Lowers 
Bleeding Without Increasing Ischemic Events 
TWILIGHT study is a double blind randomized trial, who 
examined the effect of ticagrelor alone as compared with 
ticagrelor plus aspirin with regard to clinically relevant bleed-
ing among patients who were at high risk for bleeding or an 
ischemic event and had undergone PCI enrolling 9006 patients. 
From the study population 7119 underwent randomization 
after 3 months. After 3 months of treatment with ticagrelor 
plus aspirin, patients who did not have a major bleeding or 
ischemic event continued to take ticagrelor and were randomly 
assigned to receive aspirin or placebo for 1 year. The primary 
end point was Bleeding Academic Research Consortium 
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(BARC) type 2, 3, or 5 bleeding. Between randomization and 
1 year, the incidence of the primary end point was 4.0% among 
patients randomly assigned to receive ticagrelor plus placebo 
and 7.1% among patients assigned to receive ticagrelor plus 
aspirin (hazard ratio, 0.56; 95% confidence interval [CI], 0.45 
to 0.68; P<0.001). The difference in risk between the groups 
was similar for BARC type 3 or 5 bleeding (incidence, 1.0% 
among patients receiving ticagrelor plus placebo and 2.0% 
among patients receiving ticagrelor plus aspirin; hazard ratio, 
0.49; 95% CI, 0.33 to 0.74). The incidence of death from any 
cause, nonfatal myocardial infarction, or nonfatal stroke was 
3.9% in both groups (difference, −0.06 percentage points; 95% 
CI, −0.97 to 0.84; hazard ratio, 0.99; 95% CI, 0.78 to 1.25; 
p<0.001 for non-inferiority). Therefore the study concluded that 
among high-risk patients who underwent PCI and completed 
3 months of dual antiplatelet therapy, ticagrelor monotherapy 
was associated with a lower incidence of clinically relevant 
bleeding than ticagrelor plus aspirin, with no higher risk of 
death, myocardial infarction, or stroke. We must point out 
that AstraZeneca funded this study. Interestingly these results 
were maintained even among the subgroup of patients present-
ing with NSTE-ACS (STEMI patients were excluded from 
the trial), diabetes mellitus, and those undergoing complex 
PCI. These are interesting findings, and help advance our 
understanding of the optimal duration and type of antiplatelet 
agent post-PCI. Similar findings were noted with clopidogrel 
in the SMART-CHOICE and STOPDAPT-2 trials. These 
trials are thus likely to influence future guidelines regarding 
DAPT duration post-PCI.  Mehran R et al. NEJM. 2019 Nov 
21;381(21):2032-2042. doi: 10.1056/NEJMoa1908419. Epub 
2019 Sep 26.
7. 2019 ESC Guidelines for the diagnosis and 
management of chronic coronary syndromes: 
During the annual meeting in Paris, the ESC has released 
the new 2019 Guidelines for the diagnosis and management 
of chronic coronary syndromes (CCS) that will replace the 
2013 Guidelines on stable coronary artery disease. The new 
terminology used (CCS) describes more accurately, compared 
to the previous, the different clinical presentations of the dis-
ease and is coherent with the term used to describe the acute 
coronary syndromes. The 2019 guidelines contain a number 
of new very positive issues including the central role of non-
invasive testing for myocardial ischemia, the fact the optimal 
medical therapy remains paramount and the importance of 
myocardial revascularization in patients non responsive to 
anti-anginal treatment. 
We report the most important key points:
1. Careful evaluation of patient history, including the char-
acterization of anginal symptoms, and evaluation of risk 
factors and manifestations of CVD, as well as proper 
physical examination and basic testing, are crucial for the 
diagnosis and management of CCS.
2. Unless obstructive CAD can be excluded based on clini-
cal evaluation alone, non-invasive functional imaging or 
anatomical imaging using coronary CTA may be used as 
the initial test to rule-out or establish the diagnosis of CCS.
3. Selection of the initial non-invasive diagnostic test is based 
on the PTP, the test’s performance in ruling-in or ruling-out 
obstructive CAD, patient characteristics, local expertise, 
and the availability of the test.
4. For revascularization decisions, both anatomy and func-
tional evaluation are to be considered. Non-invasive or 
invasive functional evaluation is required for the assess-
ment of myocardial ischemia associated with angiographic 
stenosis, unless very high grade (>90% diameter stenosis).
5. Assessment of risk serves to identify CCS patients at high 
event risk who are projected to derive prognostic benefit 
from revascularization. Risk stratification includes the 
assessment of LV function.
6. Patients at high event risk should undergo invasive inves-
tigation for consideration of revascularization, even if they 
have mild or no symptoms.
7. Implementation of healthy lifestyle behaviors decreases the 
risk of subsequent cardiovascular events and mortality, and 
is additional to appropriate secondary prevention therapy. 
Clinicians should advise on and encourage necessary 
lifestyle changes in every clinical encounter.
8. Cognitive behavioral interventions such as supporting 
patients to set realistic goals, self-monitor, plan how to 
implement changes and deal with difficult situations, set 
environmental cues, and engage social support are effec-
tive interventions for behavior change.
9. Multidisciplinary teams can provide patients with support 
to make healthy lifestyle changes, and address challenging 
aspects of behaviour and risk.
10. Anti-ischemic treatment must be adapted to the individual 
patient based on comorbidities, co-administered therapies, 
expected tolerance and adherence, and patient preferences. 
The choice of anti-ischemic drugs to treat CCS should be 
adapted to the patient’s heart rate, BP, and LV function.
11. Beta-blockers and/or CCBs remain the first-line drugs in 
patients with CCS. Beta-blockers are recommended in 
patients with LV dysfunction or HF with reduced ejec-
tion fraction.
12. Long-acting nitrates provoke tolerance with loss of ef-
ficacy. This requires prescription of a daily nitrate-free or 
nitrate-low interval of_10-14 h.
13. Antithrombotic therapy is a key part of secondary preven-
tion in patients with CCS and warrants careful considera-
tion. Patients with a previous MI, who are at high risk of 
ischemic events and low risk of fatal bleeding, should be 
considered for long-term DAPT with aspirin and either a 
P2Y12 inhibitor or very low-dose rivaroxaban, unless they 
have an indication for an OAC.
14. Statins are recommended in all patients with CCS. ACE 
104
HOSPITAL CHRONICLES 14(3), 2019
inhibitors (or ARBs) are recommended in the presence of 
HF, diabetes, or hypertension and should be considered 
in high-risk patients.
15. Proton pump inhibitors are recommended in patients 
receiving aspirin or combination antithrombotic therapy 
who are at high risk of gastrointestinal bleeding.
16. Efforts should be made to explain to patients the importance 
of evidence-based prescriptions to increase adherence to 
treatment, and repeated therapeutic education is essential 
in every clinical encounter.
17. Patients with a long-standing diagnosis of CCS should 
undergo periodic visits to assess potential changes in risk 
status, adherence to treatment targets, and the development 
of comorbidities. Repeat stress imaging or ICA with func-
tional testing is recommended in the presence of worsening 
symptoms and/or increased risk status.
18. Assessment of myocardial and valvular function and di-
mensions, as well as a functional test to rule-out significant 
myocardial silent ischemia, may be contemplated every 
3-5 years in asymptomatic patients with a long-standing 
diagnosis of CCS.
19. An assessment of coronary vasomotor function should 
be considered in patients with non-significant epicardial 
CAD and objective evidence of ischemia.
Knuuti J et al. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 
10.1093/eurheartj/ehz425.
STRUCTURAL HEART DISEASE 
1. PARTNER 3 and EVOLUT trials Confirm Benefits of 
TAVR Over Surgery in Low-Risk Patients 
Transcatheter aortic valve replacement (TAVR) has become 
a main stone in treatment for patients with severe aortic stenosis 
(AS) who are considered high- or intermediate risk surgical 
candidates. The use of TAVR in low-risk patients with severe 
AS is being explored as an alternative to surgical aortic valve 
replacement (SAVR). Recent results from the Medtronic Evolut 
Low Risk trial and the Placement of Aortic Transcatheter Valves 
(PARTNER) 3 trial shed light on the use of TAVR in low-risk 
surgical candidates. Both studies compared the outcomes of 
TAVR with those of SAVR in patients with severe AS and a 
low risk of death with SAVR. 
In PARTNER-3 1,000 patients randomized to either TAVR 
with a 3rd-generation balloon-expandable valve or SAVR with 
a bioprosthetic valve. The primary endpoint was the composite 
of death from any cause, stroke or re-hospitalization at one year 
after the procedure. The assigned procedure was performed 
in 950 patients. Two patients in the TAVR group and four in 
the SAVR group died during the index hospitalization. At one 
year, the primary endpoint occurred in 8.5% of the TAVR 
group compared with 15.1% of the SAVR group, meeting the 
requirements for both non-inferiority (p<0.001) and superior-
ity of TAVR vs. surgery (p<0.001). The Kaplan-Meir analysis 
of the primary endpoint components with TAVR vs. SAVR 
found mortality rates of 1.0% vs. 2.5%, stroke rates of 1.2 
% vs. 3.1%, and re-hospitalization rates of 7.3% vs. 11.0%, 
respectively, confirming both non-inferiority and superiority 
in the TAVR group. The length of hospital stay was reduced 
from 7 to 3 days with TAVR. 
In EVOLUT 1,468 patients were randomized to TAVR 
with a self-expanding bioprosthesis compared with SAVR. 
The primary endpoint was the composite of death from any 
cause or disabling stroke at 24 months. The as-treated cohort 
included 1,403 patients. At 24 months, death or disabling 
stroke occurred in 5.3 % of the TAVR group compared with 
6.7 % of the SAVR group, meeting the pre-specified criteria 
for non-inferiority. The mortality rate from any cause was 
4.5 % in both groups. The rate of disabling stroke was 1.1 
% with TAVR vs. 3.5 % with SAVR.  At 30 days, TAVR was 
statistically superior to SAVR for the secondary combined 
endpoint of all-cause mortality or disabling stroke (0.8 vs. 2.6 
%). Patients receiving TAVR had significantly better quality of 
life and hemodynamics at 30 days. Thus the Evolut Low Risk 
trial thus concluded that TAVR was statistically non-inferior 
but not superior to SAVR.
Therefore both trials provide evidence that the use of 
TAVR extends beyond the scope of high and intermediate risk 
surgical patients and is at the very least equivalent to SAVR 
in the treatment low-risk surgical candidates when using a 
transfemoral approach in patients without bicuspid aortic 
valves. Given this data, it seems reasonable to consider mov-
ing TAVR in low risk patients to a class I guideline indication 
on par with surgery for patients with severe AS. Perella P 
and Anwar S. NEJM. 2019 May 2; 380(18):1695-1705. doi: 
10.1056/NEJMoa1814052. Epub 2019 Mar 16.
2. Bicuspid Vs. Tricuspid Aortic Valve Stenosis (AS): 
Data from the Society of Thoracic Surgeons/American 
College of Cardiology (STS/ACC) Transcatheter Valve 
Therapies (TVT) Registry
As the FDA has already approved an expanded indica-
tion for several transcatheter heart valves (Sapien 3, Sapien 
3 Ultra, CoreValve Evolut R and CoreValve Evolut PRO) to 
include patients with severe aortic valve stenosis (AS) at low 
surgical risk more often we are going to phase the issue of 
bicuspid aortic valve (BiC) stenosis. However, limited data are 
available on clinical outcomes in patients with BiC AS treated 
with transcatheter aortic valve implantation (TAVR). This is 
a multicenter propensity-matched registry-based prospective 
data from the Society of Thoracic Surgeons/American Col-
lege of Cardiology (STS/ACC) Transcatheter Valve Therapies 
(TVT) Registry including 81,822 consecutive patients with 
AS undergoing TAVR for AS. 2,691 propensity-score matched 
pairs of BiC and tricuspid (TC) AS were analyzed (median 
age, 74 years; interquartile range [IQR], 66-81 years; 39.1% 
women; mean STS-predicted risk of mortality 4.9 ± 4.0% 
and 5.1 ± 4.2%, respectively). All-cause mortality was not 
significantly different between patients with BiC and TC 
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AS at 30 days (2.6% vs. 2.5%, hazard ratio [HR], 1.04; 95% 
confidence interval [CI], 0.74-1.47) and 1 year (10.5% vs. 
12.0%; HR, 0.90; 95% CI, 0.73-1.10). The 30-day stroke 
rate was significantly higher for BiC vs. TC AS (2.5% vs. 
1.6%; HR, 1.57; 95% CI, 1.06-2.33). The risk of procedural 
complications requiring open-heart surgery was significantly 
higher in the BiC vs. TC cohort (0.9% vs. 0.4%, respectively; 
absolute risk difference [RD], 0.5%; 95% CI, 0-0.9%). There 
were no significant differences in valve hemodynamics and 
there were no significant differences in moderate or severe 
paravalvular leak (PVL) at 30 days (2.0% vs. 2.4%; absolute 
RD, 0.3%; 95% CI, −1.3 to 0.7%) and 1 year (3.2% vs. 2.5%; 
absolute RD, 0.7%; 95% CI, −1.3% to 2.7%). At 1 year, there 
was no significant difference in improvement in quality of life 
between the groups overall summary score, −2.4; 95% CI, −5.1 
to 0.3; p = 0.08). This preliminary study using propensity-
matched patients from the STS/ACC TVT Registry, suggests 
no significant differences among patients with BiC vs. TC AS 
in terms of 30-day and 1-year mortality, valve hemodynam-
ics, moderate or severe PVL, or quality of life measured at 1 
year; but higher rates of stroke and procedural complications 
requiring open-heart surgery associated with BiC anatomy. This 
retrospective, registry-based study cannot control for potential 
selection bias among patients with BiC AS who underwent 
TAVR rather than surgical AVR (SAVR). The study did not 
compare outcomes for TAVR and SAVR. Given the available 
evidence and pending prospective, randomized trials, it may 
be reasonable to use TAVR in at least some patients with BiC 
AS based upon estimates of risk. Raj R. Makkar et al. JAMA. 
2019;321(22):2193-2202. doi:10.1001/jama.2019.7108
3. Mitral regurgitation and MITRA-FR vs. COAPT: 
Lessons from 2 trials with opposed results 
The overall prevalence of mitral regurgitation (MR) in the 
general population is ~2% and its etiology may be primary 
(or organic) or secondary (or functional). Secondary MR is a 
consequence of annular dilatation and geometrical distortion 
of the sub-valvular apparatus secondary to left ventricular (LV) 
remodeling associated with cardiomyopathy or coronary artery 
disease. Severe secondary MR is associated with a poor prog-
nosis in patients with chronic heart failure (HF) and reduced 
left ventricular ejection fraction (LVEF). Percutaneous mitral 
valve repair using the Mitra-Clip device has been proposed to 
correct secondary MR. Recently, the results of two randomized 
controlled trials, that is MITRA-FR (Percutaneous Repair 
with the Mitra-Clip Device for Severe Functional/Secondary 
MR) and COAPT (Cardiovascular Outcomes Assessment of 
the Mitra-Clip Percutaneous Therapy for HF Patients with 
Functional Mitral Regurgitation), assessing the efficacy and 
safety of Mitra-Clip in patients with systolic HF and severe 
secondary MR were published in the New England Journal of 
Medicine. Although, these two trials targeted the same patient 
populations with the same disease using the same device the 
results were diametrically opposed, MITRA-FR being neutral 
and COAPT being highly positive with respect to efficacy of 
the MitraClip procedure.
In light of the results of the MITRA-FR and COAPT tri-
als, it thus appears reasonable to conclude that the MitraClip 
procedure reduces HF hospitalization and mortality in patients 
meeting the following criteria: 
 - ≥ moderate-to-severe (3+) secondary MR defined as EROA 
≥30 mm2 and/or regurgitant volume >45 mL;
 - LVEF between 20% and 50% and LV end-systolic diam-
eter <70 mm;
 - Persistent HF symptoms (NYHA ≥ II) despite optimal 
(maximally tolerated) GDMT with cardiac resynchroniza-
tion and coronary revascularization if appropriate.
Furthermore, the goal of the procedure should be to ob-
tain an acute reduction of the MR severity to ≤ mild (1+) and 
the implantation of additional clips should be considered to 
achieve this goal. Indeed, a more aggressive strategy for cor-
rection of MR was applied in COAPT, as suggested by the 
larger number of clips implanted per patient in COAPT vs. 
in MITRA-FR. Furthermore, the rate of sustained reduction 
of MR was higher in COAPT than in MITRA-FR. At 1 year, 
17% of the MITRA-FR patients randomized to MitraClip had 
≥ moderate-to-severe (3+) residual MR compared with only 
5% in COAPT. The lower sustained efficacy of the MitraClip 
procedure may also have contributed to the lack of benefit of 
the intervention in MITRA-FR.
Further insight will come from the results of the Reshap-
eHF2 trial [A Clinical Evaluation of the Safety and Effective-
ness of the MitraClip System in the Treatment of Clinically 
Significant Functional Mitral Regurgitation (Reshape-HF2) 
(https://clinicaltrials.gov/ct2/show/NCT 02444338], which has 
the same inclusion criteria as those of the COAPT trial in terms 
of MR severity, with intermediary criteria COAPT and MITRA-
FR in terms of LV dysfunction severity. Philippe Pibarot, 
Victoria Delgado, and Jeroen J. Bax. European Heart Journal 
- Cardiovascular Imaging (2019) 20, 620–624 doi:10.1093/
ehjci/jez073.
4. Transcatheter strategies for tricuspid valve disease.
The tricuspid valve (TV), which is commonly referred 
to as the ‘‘forgotten valve’’ has received increasing attention 
in recent years. Transcatheter strategies for tricuspid disease 
remain in their early stages. Anatomical challenges include 
the large annulus, paucity of valve/annular calcification, ad-
jacency of the right coronary artery, and fragility of the valve 
tissue. Current approaches under investigation in feasibility 
and early phase clinical trials include edge-to-edge repair, 
coaptation enhancement, annuloplasty, heterotopic caval valve 
implantation, and percutaneous tricuspid valve replacement. 
The supporting dataset is substantially smaller than for mitral 
interventions (which is itself limited) although promising early 
outcomes have been demonstrated with the Mitra-Clip device. 
Although recent studies have suggested potential advantages 
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of transcatheter intervention compared with medical therapy, 
major questions that need to be addressed by future trials in-
clude whether earlier intervention for tricuspid regurgitation 
may be beneficial, and whether combined mitral and tricuspid 
procedures improve procedural success and clinical outcomes. 
Taramasso M, et al. J Am Coll Cardiol 2019;doi: 10.1016/j.
jacc.2019.09.028.
5. TRI-REPAIR study. Tricuspid Valve Reconstruction 
for Patients With Severe Tricuspid Regurgitation: 
6-Month Outcomes. 
This is a single-arm, multicenter, prospective trial in which 
between October 2016 and July 2017, 30 patients diagnosed 
with moderate to severe, symptomatic TR in the absence of 
untreated left-heart disease deemed inoperable were enrolled. 
TR reconstruction occurred with the use of the CaRdioband 
Transcatheter System. Six-month outcomes show that the 
system performs as intended and appears to be safe in patients 
with symptomatic and moderate to severe functional TR. Sig-
nificant reduction of TR through decrease of annular dimen-
sions, improvements in heart failure symptoms, quality of life, 
and exercise capacity were observed. Technical success was 
100%. Through 6 months, 3 patients died. Between 6 months 
and baseline, echocardiography showed average reductions of 
annular septolateral diameter of 9% (42 mm vs. 38 mm; p < 
0.01), proximal isovelocity surface area effective regurgitant 
orifice area of 50% (0.8 cm2 vs. 0.4 cm2; p < 0.01), and mean 
vena contracta width of 28% (1.2 cm vs. 0.9 cm; p < 0.01). 
Clinical assessment showed that 76% of patients improved by 
at least 1 NYHA functional class with 88% in NYHA func-
tional class I or II. Six-minute walk distance improved by 60 
m (p < 0.01), and Kansas City Cardiomyopathy Questionnaire 
score improved by 24 points (p < 0.01). Further studies are 
warranted to validate these initial promising results. (TrIcuspid 
Regurgitation RePAIr With CaRdioband Transcatheter System 
[TRI-REPAIR]; NCT02981953). Georg Nickenig et al. J Am 
Coll Cardiol. 2019 Apr 23;73(15):1905-1915. doi: 10.1016/j.
jacc.2019.01.062. 
HEART FAILURE
1. Clinical practice update on Heart Failure. 
In 2019 the ESC has published new guidelines on heart 
failure (HF). Given the amount of new information that has 
become available since 2016, the HFA of the ESC recognized 
the need to review and summarize recent developments in a 
consensus document. This expert consensus report is neither a 
guideline update nor a position statement, but rather a summary 
and consensus view in the form of consensus recommenda-
tions. This report describes how these guidance statements are 
supported by evidence, it makes some practical comments, and 
it highlights new research areas and how progress there might 
change the clinical management of HF. We report interesting 
data regarding Heart Failure patients:
A. SGLT2 inhibitors in type 2 diabetes mellitus and Heart 
Failure. Data from clinical trials
EMPA-REG enrolled 7020 patients with T2DM, about 10% 
of who had HF (LVEF was not measured) and showed that 
empagliflozin reduced the risk of hospitalization for HF and 
mortality. Within a few weeks of initiating empagliflozin, body 
weight, and blood pressure fell and hematocrit rose, consist-
ent with a diuretic effect. Subsequent RCTs of other SGLT2i 
in T2DM had similar findings. Meta-analyses suggested that 
SGLT2i were the hypoglycaemic agents most likely to reduce 
incident HF, whilst observational data raises concerns about 
insulin therapy. A meta-analysis of RCTs of empagliflozin, 
canagliflozin, and dapagliflozin for T2DM, including >30 000 
patients, showed benefit, at least for those with established CV 
disease. For the outcome of hospitalization for HF or CV death, 
the annual rate was about 0.6% for the 13 672 patients with 
multiple risk factors but without established CV disease, about 
3% for the 20 650 patients with established atherosclerotic 
disease and about 6% for 3891 patients with HF at baseline; 
the relative risk reductions with SGLT2i in these populations 
were 16%, 24%, and 29%, respectively, without evidence 
of heterogeneity amongst agents. The largest of these trials, 
DECLARE, included 17 160 patients of whom 671 had HFrEF 
and 1316 had HFpEF or an unspecified LVEF. In a subgroup 
analysis, dapagliflozin reduced hospitalizations for HF and 
CV mortality for HFrEF but not for other patient-groups. 
DAPA-HF enrolled 4744 patients and followed them 
for a median of 18.3 months, demonstrating that addition of 
dapagliflozin to guideline-recommended therapy for HFrEF-
reduced hospitalizations for HF by 30% and mortality (mainly 
cardiovascular) by 18%, preventing 3–5 hospitalizations and 
1–2 deaths per 100 patients treated per year. Patients were 
somewhat less likely to experience serious adverse events, 
especially renal, with dapagliflozin compared with placebo. 
The benefits appeared consistent across subgroups, although 
patients with evidence of more severe congestion (worse 
NYHA class or higher NT-pro-BNP) may have received less 
benefit. Importantly, benefits were similar for those with and 
without T2DM and regardless of age.
Dapagliflozin also improved quality of life, an effect that 
was confirmed in a smaller RCT (DEFINE) that followed 263 
patients for 12 weeks; about one in six patients got a meaningful 
benefit, either prevention of worsening or an improvement in 
symptoms, compared with placebo. In DAPA-HF, the placebo-
corrected decline in weight between baseline and 8months 
was 0.87 kg and this was associated with a small fall in NT-
proBNP and systolic blood pressure and a small increase in 
haematocrit and serum creatinine. These findings are again 
consistent with the belief that SGLT2i exert at least some 
of their benefits by enhancing diuresis, through an osmotic 
effect of glycosuria or by interfering with sodium-hydrogen 
exchange in the nephron. The effects of SGLT2i appear early, 
consistent with an immediate hemodynamic effect. However, 
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alternative or additional explanations for the effect of SGLT2i 
have been proposed. A small RCT suggested that empagliflozin 
stimulated production of erythropoietin leading to a rise in 
hematocrit and a fall in ferritin, a marker.
B. MitraClip and heart failure, 
(see also Mitral regurgitation and MITRA-FR vs. COAPT): 
More experience and further data from RCTs may improve 
patient selection (RESHAPE-HF2: https://clinicaltrials.gov/
ct2/show/NCT02444338). However, optimizing guideline-
recommended therapy, including diuretic dose, may cause 
mitral regurgitation secondary to dilation of the LV and mitral 
ring to improve or resolve. Other technologies for secondary 
mitral and tricuspid regurgitation are being developed.
C. Atrial Fibrillation in Heart Failure: 
About a third of outpatients, perhaps more for those with 
HFpEF, and more than half of those admitted with HF will be 
in AF, which is associated with an adverse prognosis even after 
correcting for age and other risk factors. Controversy continues 
over whether medical management focused on rate control or 
restoration of sinus rhythm is the better strategy for AF and HF. 
In practice, the strategy needs to be tailored to the patient. When 
AF is the driver of symptoms and worsening cardiac function, 
restoration of sinus rhythm might be appropriate but when AF 
reflects the progression of underlying cardiac dysfunction, it 
may not. For new-onset or paroxysmal AF associated with a 
clear deterioration in symptoms, restoration of sinus rhythm 
may be warranted to improve symptoms. For long-standing 
AF and HF with markedly dilated atria, sustained restoration 
of sinus rhythm and atrial contraction is less likely. Optimal 
pharmacological management includes anticoagulation avoid-
ing toxic anti-arrhythmic agents and lenient ventricular rate 
control. Beta-blockers are the agent of choice for rate control, 
a resting day-time ventricular rate of 70–90bpm is preferred, 
which may require only modest doses; digoxin should be used 
sparingly, if at all. Unfortunately, RCTs of rate vs. rhythm 
control for AF HF to optimize the rate control strategy in the 
above fashion. A meta-analysis of RCTs of rate vs. rhythm 
control included four trials (n= 2486) comparing pharmaco-
logical rhythm to rate control found no difference in mortality 
or thromboembolic events but an increase in hospitalizations, 
often due to recurrent AF, in the rhythm control group. Six 
trials (n= 1112) comparing AF ablation with rate control 
reported reductions in mortality (0.51; 95% CI 0.36–0.74), 
hospitalizations (0.44; 95% CI 0.26–0.76), and stroke (0.59: 
95% CI 0.23–1.51) and an improved quality of life.  However, 
none of the trials individually had a robust result, patients were 
highly selected and the rate control strategy was not optimal. 
As such, this meta-analysis should be considered hypothesis 
generating. Further trials are required with greater involvement 
of heart failure physicians.
D. Implanted electrical device in Heart Failure patients:
The controversy over the role of high-energy devices for HF 
continues. Long-term follow-up of cardiac resynchronization 
therapy (CRT) in a French Registry showed a low rate of sud-
den death amongst patients who received CRT-Pacing (without 
a defibrillator). A systematic review of observational studies 
and RCTs reported that differences in the rate of sudden death 
with CRT-Pacing and CRT-D were narrowing. RCTs comparing 
CRT-Pacing and CRT-D are underway. Whether myocardial 
scar found on cardiac magnetic resonance imaging identifies 
patients with more to gain from an implantable cardioverter 
defibrillator (ICD) is also under investigation  (CMR_GUIDE; 
https://clinical trials.gov/ct2/show/NCT01918215). Retrospec-
tive analysis of SCDHeFT found that patients with T2DM did 
not benefit from an ICD. An individual patient-data meta-
analysis confirmed a reduction in sudden death with MRA. 
A systematic review identified 22 studies with post-mortem 
interrogation of ICDs; the analysis suggested that 24% of 
sudden deaths were not arrhythmic. A substantial multi-point 
pacing trial failed, so far, to show improvements in the clinical 
or echocardiographic response to CRT.
E. Rehabilitation: 
Systematic reviews suggest that exercise-based rehabilita-
tion can improve patients’ well-being and exercise capacity 
and reduce HF related and all-cause hospitalization but may 
not reduce mortality, despite potentially improving adherence 
to treatment. The best and most cost-effective service-model 
is a topic of active research. 
John G.F. Cleland et al. European Heart Journal (2020) 41, 
1232–1248. doi:10.1093/eurheartj/ehz949.
ΑRRYTHMIAS 
1. 2019 ESC Guidelines for the management of patients 
with supraventricular tachycardia. The Task Force 
for the management of patients with supraventricular 
tachycardia of the European Society of Cardiology 
(ESC)
This is the first guideline update for SVT by ESC in 16 
years. The following are key points to remember from the 2019 
European Society of Cardiology (ESC) guidelines for the man-
agement of patients with supraventricular tachycardia (SVT):
A. Amiodarone and digoxin are no longer mentioned in 
the new guidelines for the acute management of narrow 
complex tachycardia. Sotalol and lidocaine have been 
removed from the acute management of wide complex 
tachycardia algorithm.
B. Verapamil/diltiazem and catheter ablation are no longer 
recommended for inappropriate sinus tachycardia. Ivabra-
dine alone, beta-blocker alone, or both agents taken to-
gether should now be considered in symptomatic patients 
(Class IIa).
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C. Procainamide, sotalol, and digoxin are no longer recom-
mended for the acute management of focal atrial tachycar-
dia (AT). Amiodarone, sotalol, and disopyramide are not 
recommended for chronic suppression of focal AT. Catheter 
ablation is recommended for recurrent focal AT, especially 
if incessant or causing tachycardia cardiomyopathy. Beta-
blockers should be considered for recurrent focal AT or 
atrial flutter, if ablation is not possible or successful.
D. For multifocal AT, treatment of an underlying condition is 
recommended as a first step (Class I). Verapamil, diltiazem, 
or a selective beta-blocker should be considered (Class 
IIa). Atrioventricular (AV) nodal ablation followed by 
biventricular or His-bundle pacing should be considered 
for patients with left ventricular dysfunction due to recur-
rent multifocal AT refractory to drug therapy (Class IIa).
E. Dofetilide, sotalol, flecainide, propafenone, procainamide, 
quinidine, and disopyramide are no longer recommended 
for chronic management of atrial flutter in the new guide-
lines. Patients with atrial flutter without atrial fibrillation 
(AF) should be considered for anticoagulation, but the 
threshold for initiation is not established (Class IIa).
F. In all re-entrant and most focal arrhythmias, catheter abla-
tion should be offered as an initial choice to patients, after 
having explained in detail the potential risks and benefits. 
In post-AF ablation ATs, focal or macro–re-entrant, abla-
tion should be deferred for >3 months after AF ablation, 
when possible.
G. Multiple drugs have been removed from both the acute and 
chronic management of AV nodal re-entrant tachycardia 
(AVNRT). Verapamil, diltiazem, and beta-blockers remain 
as options for the chronic management of AVNRT, but they 
were downgraded from Class I to Class IIa.
H. Catheter ablation is recommended in asymptomatic pa-
tients in whom electrophysiology testing with the use of 
isoprenaline identifies high-risk properties, such as short-
est pre-excited RR interval during AF≤250ms, accessory 
pathway effective refractory period <250ms, multiple 
accessory pathways, and an inducible accessory pathway-
mediated tachycardia (Class I).
I. Flecainide or propafenone should be considered for preven-
tion of SVT in patients with WPW syndrome and without 
ischemic or structural heart disease (Class IIa).
J. SVTs have been reported as risk factors for sudden car-
diac death in patients with adult congenital heart disease 
(ACHD). In ACHD, anticoagulation for focal AT or atrial 
flutter should be similar to that for patients with AF. Cath-
eter ablation in experienced centers should be considered. 
Sotalol is not recommended as a first-line antiarrhythmic 
drug due to an increased risk of proarrhythmia and mortality 
(Class III). Flecainide and propafenone should be avoided 
in patients with left bundle branch block, or ischemic or 
structural heart disease (Class III).
K. In postural orthostatic tachycardia syndrome, a regular 
and progressive exercise program should be considered 
(Class IIa). The consumption of up to 2-3 L of water and 
10-12 g of sodium chloride daily, as well as midodrine, 
low dose non-selective beta-blocker, pyridostigmine, and 
ivabradine may be considered (Class IIb).
L. Vagal maneuvers and adenosine are the treatments of 
choice for the acute therapy of SVT, and may also provide 
important diagnostic information.
M. In post-AF ablation ATs, focal or macro-re-entrant, abla-
tion should be deferred for  >_3 months after AF ablation, 
when possible.
N. If possible, avoid all antiarrhythmic drugs during the first 
trimester of pregnancy. If beta-blockers are necessary, use 
only beta-1 selective agents (but not atenolol). If ablation is 
necessary during pregnancy, use non-fluoroscopic mapping.
O. Patients with macro-re-entrant tachycardias following 
atrial surgery should be referred to specialized centers 
for ablation.
P. Ablate AVNRT, typical or atypical, with lesions in the 
anatomical area of the nodal extensions, either from the 
right or left septum. AVNRT, typical or atypical, can now 
be ablated with almost no risk of AV block.
Brugada J et al. Eur Heart J. 2020 Feb 1;41(5):655-720. doi: 
10.1093/eurheartj/ehz467.
PREVENTIVE CARDIOLOGY
1. 2019 ESC/EAS Guidelines for the management 
of dyslipidemias: lipid modification to reduce 
cardiovascular risk: The Task Force for the management 
of dyslipidemias of the European Society of Cardiology 
(ESC) and European Atherosclerosis Society (EAS)
The 2019 Joint European Society of Cardiology (ESC)/Eu-
ropean Atherosclerosis Society (EAS) Dyslipidemia Guidelines 
were released on 31 August during the ESC Congress, Paris, 
France. These novel ESC/EAS Guidelines on lipids provide 
important new advice on patient management, which should 
enable more clinicians to efficiently and safely reduce CV risk 
through lipid modification emphasizing that lower LDL-C is 
better. Herein we present the most important key messages 
of the new guidelines regarding: 
A. Cholesterol and risk
Prospective studies, randomized trials, and Mendelian 
randomization studies have all shown that raised LDL-C is 
a cause of ASCVD. Throughout the range of LDL-C levels, 
‘lower is better’ with no lower threshold, at least down to _1 
mmol/L. Lowering LDL-C may yield worthwhile benefits in 
patients with average or below average LDL-C who are al-
ready receiving LDL-C-lowering treatment. The proportional 
reduction in ASCVD risk achieved by lowering LDL-C (e.g. 
with a statin, ezetimibe, or PCSK9-inhibitor) depends on the 
absolute reduction in LDL-C, with each 1 mmol/L reduction 
corresponding to a reduction of about one-fifth in ASCVD.
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B. PCSK-9 inhibitors
Large trials have shown that PCSK9 inhibitors further 
reduce ASCVD risk when given on top of statin-based therapy 
and their use may need to be restricted to those at the highest 
risk for ASCVD (Subgroup analyses of the FOURIER and 
ODYSSEY OUTCOMES trials).
C. Use of cardiac imaging for risk stratification
CAC score assessment with CT may be helpful in reaching 
decisions about treatment in people who are at moderate risk 
of ASCVD. Obtaining such a score may assist in discussions 
about treatment strategies in patients where the LDL-C goal 
is not achieved with lifestyle intervention alone and there is 
a question of whether to institute LDL-C-lowering treatment. 
Assessment of arterial (carotid or femoral) plaque burden on ul-
trasonography may also be informative in these circumstances.
D. Use of Apo-B in risk stratification
Apo-B may be a better measure of an individual’s expo-
sure to pro atherogenic lipoproteins, and hence its use may 
be particularly helpful for risk assessment in people where 
measurement of LDL-C underestimates this burden, such as 
those with high TG, DM, obesity, or very low LDL-C.
E. Use of Lp(a) in risk stratification: A one-off measure-
ment of Lp(a) may help to identify people with very high 
inherited Lp(a) levels who may have a substantial lifetime risk 
of ASCVD. A high Lp(a) plasma level may also be helpful in 
further risk stratification of patients at high risk of ASCVD, 
in patients with a family history of premature CVD, and to 
determine treatment strategies in people whose estimated 
risk is on the border of risk categories. The guidelines have 
emphasized that individuals with very high Lp(a), indicative 
of an inherited lipid disorder, are likely to have a lifetime 
ASCVD risk similar to that of individuals with heterozygous 
FH. The new emphasis on Lp(a) is important, given the fact 
that novel treatments that are specific to this lipoprotein 
abnormality are now entering phase III clinical trials in high 
and very high-risk patients. Current options for treatment of 
high Lp(a) are limited to the PCSK9 inhibitors which have 
been shown to reduce levels by 25-30% on average, with or 
without background statin therapy.
F. Intensification of treatment goals
It is important to ensure that treatment of the highest-risk 
patients achieves the largest LDL-C reduction possible. These 
Guidelines aim to support this by setting both a minimum 
percentage LDL-C reduction (50%) and an absolute LDL-C 
treatment goal of <1.4 mmol/L (<55mg/dL) for very-high-risk 
patients, and <1.8 mmol/L (<70 mg/dL) for high-risk patients. 
It is recommended that FH patients with ASCVD or who 
have another major risk factor are treated as very-high-risk, 
and those with no prior ASCVD or other risk factors as high-
risk. Additionally, there has been further information from 
the IMPROVE-IT trial with ezetimibe, which demonstrated 
enhanced absolute cardiovascular benefit in very high-risk 
individuals with diabetes compared with those without, re-
flecting the higher absolute risk of this group.
G. Treatment of patients with recent ACS
New randomized trials support a strategy of intensification 
of LDL-C-lowering therapy in very-high-risk patients with 
ACS (MI or unstable angina). If the specified LDL-C treatment 
goal is not achieved after 4-6 weeks with the highest tolerated 
statin dose and ezetimibe, it is appropriate to add a PCSK9 
inhibitor. Moreover, If patients experience a second vascular 
event within 2 years (not necessarily of the same type as the 
first event) on maximally tolerated statin therapy, an LDL-C 
goal of <1.0 mmol/L (<40 mg/dL) may be considered.
H. Safety of low LDL cholesterol concentrations: To 
date there are no known adverse effects of very low LDL-C 
concentrations [e.g. <1 mmol/L (40 mg/dL)].
I. Management of statin ‘intolerance’
While statins rarely cause serious muscle damage (myo-
pathy, or rhabdomyolysis in the most severe cases), there 
is much public concern that statins may commonly cause 
less serious muscle symptoms. Such statin ‘intolerance’ is 
frequently encountered by practitioners and may be difficult 
to manage. However, placebo-controlled randomized trials 
have shown very clearly that true statin intolerance is rare, 
and that it is generally possible to institute some form of statin 
therapy (e.g. by changing the statin or reducing the dose) in 
the overwhelming majority of patients at risk of ASCVD.
J. Statin treatment for older people
A meta-analysis of randomized trials has shown that the 
effects of statin therapy are determined by the absolute reduc-
tion in LDL-C as well as the baseline ASCVD risk, and are 
independent of all known risk factors, including age. Statin 
therapy in older people should therefore be considered accord-
ing to the estimated level of risk and baseline LDL-C, albeit 
with due regard to an individual’s underlying health status and 
the risk of drug interactions. There is less certainty about the 
effects of statins in individuals aged >75 years, particularly 
in primary prevention. Statin therapy should be started at a 
low dose if there is significant renal impairment and/or the 
potential for drug interactions, and then titrated upwards to 
achieve LDL-C treatment goals.
K. Triglyceride management
While statin treatment remains the first choice for managing 
high triglycerides (TG, >200 mg/dL or 2.3 mmol/L), the new 
guidelines have taken account of evidence from REDUCE-IT and 
recommend n-3 PUFAs (particularly icosapent ethyl 2x2g daily) 
in high-risk patients with persistently elevated TG (between 
135 - 499mg/dL or 1.5 and 5.6 mmol/L) despite statin treatment. 
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In high-risk patients at LDL-C goal with TG >200 mg/dL or 
>2.3 mmol/L, fenofibrate or bezafibrate may be considered in 
combination with statins. Mach F, et al. Eur Heart J. 2020 Jan 
1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
2. 2019 ESC Guidelines on diabetes, pre-diabetes, and 
cardiovascular diseases developed in collaboration with 
the EASD
The global prevalence of diabetes mellitus (DM) has quadru-
pled over the past few decades, from an estimated 108 million 
adults living with diabetes in 1980 to 422 million adults living 
with diabetes in 2014. Just as worrying, the global burden of 
diabetes is projected to further increase by 10% in 2040. This 
poses a major challenge to societies and health care authorities 
as diabetes increases the risk for several diseases, including 
cardiovascular disease (CVD). Indeed, the total economic cost 
associated with DM was $327 billion in 2017 in the US alone. 
Clear and evidence-based recommendations for how to manage 
patients with diabetes have never been more important. The 
European Society of Cardiology (ESC), in collaboration with the 
European Association for the Study of Diabetes (EASD) released 
2019 guidelines for the prevention and management of CVD 
in patients with pre-diabetes and diabetes. The following Table 
summarizes the CVD risk categories, which developed from the 
2016 ESC guidelines on CVD prevention in clinical practice.
Very high risk High risk Moderate risk
Patients with DM 
and CVD or DM 
with target organ 
damage.*
Patients with DM 
with three or more 
major risk factors 
or with type 1 DM 
duration of >20 
years
Patients with DM 
duration of ≥10 
years without 
target organ 
damage plus any 
other additional 
risk factor
Young patients 
(type 1DM aged 
<35 years or type 
2DM aged <50 
years) with DM 
duration of <10 
years without other 
risk factors 
*Proteinuria or kidney failure (estimated GFR <30 mL/min/1.73m2), LV 
hypertrophy, or retinopathy
Herein we present the most important key messages of the 
new guidelines regarding:
A. Glucose Lowering Management
Since the prior ESC guidelines published in 2013, there 
has been an unprecedented increase in new evidence indicating 
cardiovascular benefits from the use of novel glucose-lowering 
drugs based on large-scale cardiovascular outcome trials. In gen-
eral, the new 2019 ESC recommendations for glucose lowering 
treatments are closely linked to recent results from the CVOTs. 
Thus, an SGLT-2 inhibitor or GLP1-RA should be immediately 
initiated or added to existing metformin treatment in patients with 
DM and CVD, or in patients at high or very high risk to reduce 
CV events. Metformin is the preferred initial glucose-lowering 
agent for the treatment of type 2 DM. The guideline also provides 
specific recommendations for SGLT2 and GLP1-RA based on 
results from individual CVOTs. Accordingly:
 - SGLT2 inhibitors such as empagliflozin, canagliflozin, or 
dapagliflozin are recommended to lower the risk of heart 
failure hospitalization and to reduce the progression of 
diabetic kidney disease. Empagliflozin is recommended in 
patients with prevalent CVD, to reduce the risk of death.
 - GLP1-RAs such as liraglutide, semaglutide and dulaglutide 
are recommended in patients with DM and CVD, or who 
are at very high/high CVD risk, to reduce CVD events. 
In addition, liraglutide has shown to significantly reduce 
CV death in DM and CVD, or for patients at very high/
high CV risk.
The choice of drug to reduce CV events should be prior-
itized and individualized based on the presence of risk factors 
and CVD in patients with DM. For glycemic control, HbA1c 
l< 7% is advised for most patients, while a target of 8% or 
≤9% may be adequate for elderly patients.
B. Lipid Management
The 2019 ESC diabetes guidelines endorse the same 
principle for management of blood cholesterol as the 2019 
dyslipidemia guidelines, that is, by providing differentiated 
treatment targets for low-density lipoprotein cholesterol (LDL-
C) based on estimated risk for CVD. These LDL-C targets have 
been lowered compared to the preceding guideline:
 - Moderate risk: LDL-C <2.6 mmol/L (<100mg/dL) 
 - High risk: LDL-C <1.8 mmol/L (<70mg/dL) and LDL-C 
reduction of at least 50% is recommended
 - Very high risk: LDL-C <1.4 mmol/L (<55mg/dL) and 
LDL-C reduction of at least 50% is recommended
To reach these targets, most patients will qualify for statin 
treatment. Currently, a PCSK9 inhibitor is recommended in 
very high-risk patients who have persistently high LDL-C 
levels even with maximal dose of statin and ezetimibe therapy 
or in patients who have statin intolerance.
C. Blood Pressure Management
As with lipid targets, the targets for blood pressure levels 
have been lowered in the new guidelines. Thus, a systolic 
blood pressure (SBP) goal of 130 mmHg (<130mmHg if 
well tolerated), and a diastolic blood pressure (DBP) goal of 
<80mmHg is recommended, compared to a previous target 
of <140/85 mmHg for all patients. In older adults aged >65 
years, SBP target range of 130-139 mmHg is recommended. 
The guidelines emphasize an individualized approach for 
hypertension management. Angiotensin-converting enzyme 
inhibitor or angiotensin receptor blocker is recommended as 
first line therapy for BP control in DM patients.
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D. Antiplatelet Therapy
The 2019 ESC guideline does not provide strong recom-
mendations for antiplatelet therapy in DM patients without 
CVD. Therefore aspirin for primary prevention is not recom-
mended in patients with DM at moderate CV risk. However, 
aspirin (75-100 mg/day) for primary prevention may be consid-
ered in patients with DM at very high/high risk in the absence 
of clear contraindications (IIb). In addition, concomitant use of 
a proton pump inhibitor is recommended in patients receiving 
aspirin monotherapy, DAPT, or oral anticoagulant monotherapy 
who are at high risk of gastrointestinal bleeding finally, pro-
longation of DAPT beyond 12 months should be considered 
for ≤3 years in patients with DM at very high risk who have 
tolerated DAPT without major bleeding complications.
E. Imaging
Screening for coronary artery disease (CAD) in asympto-
matic patients with DM remains debatable. According to the 
new guidelines, screening of CAD with computed tomography 
coronary angiography (CTCA) or functional imaging such 
as radionuclide myocardial perfusion imaging, stress cardiac 
magnetic resonance imaging, or exercise or pharmacological 
stress echocardiography may be considered (IIb). Additionally, 
coronary artery calcium (CAC) score may be considered as 
a risk modifier in the CVD risk assessment of asymptomatic 
patients at moderate risk (IIb).
D. Revascularization strategies
Angiographic studies have shown that patients with DM 
are more likely to have left main and multivessel CAD (MVD), 
and that coronary pathology is more frequently diffuse and 
involves the small vessels. The indications for myocardial 
revascularization, for both symptomatic and prognostic rea-
sons, are the same in patients with and without DM (IA), and 
have been summarized in the 2018 ESC/ EACTS Guidelines 
on myocardial revascularization (see previous text). The ap-
propriate revascularization modality in patients with DM and 
MVD should be discussed by the Heart Team, taking into con-
sideration individual cardiac and extracardiac characteristics, 
as well as preferences of the well-informed patient. However, 
in patients with DM with low complexity of coronary anatomy 
(SYNTAX score ≤22), PCI using DES has achieved similar 
outcomes to CABG with respect to death and the composite of 
death, MI, or stroke. Therefore, PCI prevails to CABG in 1VD 
or 2VD without proximal LAD stenosis (IC vs. IIB), while has 
equivocal indication in LM disease and low SYNTAX score 
representing a good alternative. In patients with DM and 3VD 
CABG prevails PCI (IC vs. IIB). Overall, current evidence 
indicates that in stable patients with coronary anatomy suit-
able for both procedures and low predicted surgical mortality, 
CABG is superior to PCI in reducing the composite risk of 
death, MI, or stroke, as well as death. CABG is recommended 
for intermediate-to-high anatomical complexity (SYNTAX 
score >22) with the PCI being a good alternative in case of 
intermediate disease complexity (SYNTAX scorec 23 -32). 
While in case of HFrEF and DM, and two- or three-vessel 
CAD, CABG is the recommended approach. Although newer-
generation DESs have improved outcomes in patients with 
DM, RCTs are needed to determine whether they can reduce 
the gap in outcomes between CABG and PCI. The best surgi-
cal coronary revascularization strategy and graft selection in 
patients with DM is still subject to debate.  In case of CABG 
the first choice should be the internal mammary artery, and its 
impact on survival when grafted to the left anterior descending 
(LAD) coronary artery and the radial artery may be preferred 
as a second graft in view of better long-term patency of the 
radial artery compared with the saphenous vein, but further 
studies are needed (see the 2018 ESC/EACTS Guidelines on 
myocardial revascularization for further information). Inter-
estingly in the Arterial Revascularization Trial (ART) which 
compared the BIMA with SIMA and an additional veins in 
1554 patients, at 10 years showed no significant differences 
in the rate of death or the composite outcome of death, MI, 
or stroke suggesting that vein grafts is always a good option.
F. Heart failure and diabetes
Patients with DM are at greater risk of HF with reduced 
ejection fraction (HFrEF) or HF with preserved ejection fraction 
(HFpEF); conversely, HF increases the risk of DM. Indeed, 
findings from a large pan-European registry indicated that 
36% of outpatients with stable HF had DM, while in patients 
hospitalized for acute HF, DM was present in ≤50%. Major 
causes of HF in patients with DM are CAD, CKD, hyperten-
sion, and direct effects of insulin resistance/ hyperglycaemia 
on the myocardium.
 - The coexistence of DM and HF imparts a higher risk of 
HF hospitalization, all-cause death, and CV death.
 - Guideline-based medical and device therapies are equally 
effective in patients with and without DM; as renal dys-
function and hyperkalaemia are more prevalent in patients 
with DM, dose adjustments of some HF drugs (e.g. RAAS 
blockers) are advised. 
 - Aliskiren (a direct renin inhibitor) is not recommended 
for patients with HFrEF and DM because of a higher risk 
of hypotension, worsening renal function, hyperkalaemia, 
and stroke.
 - First-line treatment of DM in HF should include metformin 
and SGLT2 inhibitors; conversely, saxagliptin, pioglita-
zone, and rosiglitazone are not recommended for patients 
with DM and HF.
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